The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.

A high-throughput, scalable, low-cost, on-chip microfluidic potency assay for nondifferentiated cells such as human mesenchymal stromal cells (hMSCs) with improved functional predictive power and recapitulation of in vivo secretory responses compared to traditional approaches. By comparison of hMSC secretory responses to functional hMSC-medicated immune cell suppression, on-chip microfluidic potency markers are identified with improved functional predictive power compared to traditional planar methods.

The present invention provides a method of diagnosis or prognosis endometrial carcinoma, the method comprising determining the level of expression of MMP9 in a uterine aspirate fluid sample from the female genital tract. The present invention further provides kits for the diagnosis of the disease.

The present invention is directed to fluorescent protein biosensors based on oligonucleotide cross reactive sensor arrays including a selective and a non-selective protein surface binding domain for protein detection. Interaction of different protein isoforms with the sensors of this invention yields a unique optical signature for each protein. The unique optical signature allows differentiating between closely related protein isoforms and diagnosing diseases and disorders associated with the proteins also in biofluids.

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an l=g light chain (or functional fragment thereof).

The methods disclosed herein relate to an improved tool incorporating platelet count into a multi-biomarker based outcome risk stratification model for evaluating mortality risk in pediatric patients having sepsis. The methods described here are useful for treating sepsis, for point of care clinical decision support, for stratifying septic shock patients based on baseline mortality risk, and for clinical trial design, among other uses.

The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.

The present disclosure relates to compositions and methods for identifying a subject at risk for traumatic brain injury. In particular, the instant disclosure is directed to identification of the levels of the proteins MMP-9 (Matrix Metallopeptidase 9), NSE (Neuron Specific Enolase) and VCAM-1 (Vascular Cell Adhesion Molecule 1) in a subject sample, and correlation of these protein levels with the presence of intracranial injury. In certain embodiments, subject age, gender and hemoglobin level are also correlated with the presence of intracranial injury.

The invention relates to biomarkers and a method of diagnosing or monitoring depression, anxiety disorder or other psychotic disorder.

Described herein is an enzyme detection device for use in the detection of enzyme activity in a test sample. Also provided are indicator molecules for use in the detection of enzyme activity, particularly enzyme cleavage activity, in a test sample, and to methods for detecting the presence of enzyme activity.